EXTON, Pa.--(BUSINESS WIRE)--Morphotek, Inc., a U.S. subsidiary of Eisai Co., Ltd., announced today that the company has received approval of protocol by the Paul-Ehrlich-Institute (PEI), Germany’s regulatory authority charged with biologics development oversight, for clinical trial Phase II site selections in Heidelberg and Frankfurt. These sites will be used to study MORAb-003, a humanized monoclonal antibody that targets the folate receptor alpha (FRA), a target over-expressed in more than 90 percent of ovarian cancers and a number of other solid tumors. The study will investigate the efficacy of MORAb-003 in women who are in their first relapse of ovarian cancer and allow for the recruitment of subjects in Germany to participate in the MORAb-003 Phase II trial.
